Incannex Healthcare (IXHL) SEC Filings

Incannex Healthcare Inc. asks stockholders to elect Joel Latham and Troy Valentine as Class III directors for three-year terms ending at the 2029 annual meeting and to ratify Grant Thornton Audit Pty Ltd as its independent registered public accounting firm for the fiscal year ending June 30, 2027. The board recommends both proposals. The virtual annual meeting is scheduled for December 17, 2026, at 10:00 a.m. Gulf Standard Time, with attendance by live audio webcast after advance registration. Common stockholders of record on October 22, 2026, may vote; 12,544,627 shares were outstanding and entitled to vote on that date, with one vote per share.

Reported fiscal 2026 total compensation was $6,527,200 for Chief Executive Officer Joel Latham, including $5,200,000 in stock awards, and $466,456 for Chief Financial Officer Joseph Swan. Grant Thornton audit fees were $335,885 for fiscal 2026 and $307,852 for fiscal 2025.

Incannex Healthcare Inc. (IXHL) is a clinical-stage biopharmaceutical company advancing IHL-42X for obstructive sleep apnea (OSA), while evaluating next steps for PSX-001 in generalized anxiety disorder (GAD) and IHL-675A in inflammatory conditions. The FDA granted IHL-42X Fast Track designation in December 2025. Its DReAMzz Phase 2 dose-confirmation study is enrolling approximately 120 subjects at 14 U.S. sites and evaluates nine dose combinations; completion is estimated for mid-2027, with results expected to inform a planned Phase 3 design.

In RePOSA, the Phase 2 portion was completed in July 2025, and Incannex reported statistically significant AHI reductions and improvements in several patient-reported measures. In the completed PsiGAD1 Phase 2 trial, the company reported an average 12.8-point reduction in HAM-A anxiety scores sustained over an 11-week follow-up. The Australian Phase 2 trial of IHL-675A was terminated after recruitment challenges, and the company said the data were insufficient for conclusions on safety or efficacy. The USPTO granted a key patent for IHL-42X in June 2026.

Incannex Healthcare Inc. (IXHL) reported a broad corporate update covering clinical progress, intellectual property and capital resources. The company has begun dosing patients in DReAMzz, a Phase 2 crossover dose‑optimization study of IHL‑42X for obstructive sleep apnea at 13 U.S. sites under Institutional Review Board approval, with an FDA‑reviewed protocol intended to support a later Phase 3 registration program.

Incannex highlighted prior positive Phase 2 RePOSA data in 121 subjects, where both low‑ and high‑dose IHL‑42X showed statistically significant improvements versus placebo in apnea‑hypopnea index and oxygen desaturation index, and noted the program’s Fast Track designation granted in December 2025. The U.S. Patent and Trademark Office has granted a composition and methods patent for IHL‑42X expiring July 9, 2040.

The company also reported progress for PSX‑001, its synthetic psilocybin candidate for generalized anxiety disorder, backed by a 73‑subject positive Phase 2 study, an open U.S. Investigational New Drug application for a Phase 2b trial, and recent regulatory engagement in the UK. As of August 31, 2026, Incannex held approximately $70 million in cash and cash equivalents with no debt, supported by more than A$11.2 million in 2026 Australian R&D tax incentive refunds.

Incannex Healthcare Inc. (IXHL) reports a clinical milestone for its lead sleep apnea candidate IHL-42X. The company has dosed the first patient in DReAMzz, a Phase 2 crossover dose-optimization study evaluating an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea.

The new study follows the earlier Phase 2 RePOSA trial, where IHL-42X produced statistically significant reductions in apnea-hypopnea index (AHI) versus placebo, with individual AHI reductions of up to 83% and an exceptional safety profile. IHL-42X has FDA Fast Track designation, and Incannex has activated 14 clinical sites in the United States for DReAMzz, with drug manufactured and regulatory and operational preparations completed.

DReAMzz is intended to characterize dose-response, optimize the treatment regimen, and support the design of a planned Phase 3 program. Incannex highlights IHL-42X as a potential oral treatment option for the large population affected by obstructive sleep apnea and positions this Phase 2 work as a step toward late-stage development.

Polar Asset Management Partners Inc., an Ontario, Canada-based investment advisor, reported beneficial ownership of Incannex Healthcare Inc. common stock. The position relates to 900,000 shares issuable upon the exercise of warrants, representing 7.0% of Incannex’s common stock class. Polar reports sole voting and sole dispositive power over these 900,000 warrant-linked shares, with no shared voting or dispositive power. The shares are directly held by Polar Multi-Strategy Master Fund, a Cayman Islands exempted company, for which Polar acts as investment advisor.

Incannex Healthcare Inc. reported receiving a final A$5,102,788.30 cash refund under the Australian Government’s Research and Development Tax Incentive Program, following approval of its overseas findings and amendment of its FY25 income tax return. Together with a previously received A$6,039,162.43 refund, the company has obtained more than A$11.2 million in non-dilutive capital during 2026.

The company states that this funding enhances its strong cash position and debt-free balance sheet, providing additional financial flexibility to advance its clinical pipeline, including IHL-42X, IHL-675A and PSX-001, while pursuing shareholder-focused capital allocation initiatives.

Incannex Healthcare Inc. has begun screening participants in its DReAMzz randomized, crossover Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea. The first group of trial sites has approvals to screen patients, with additional sites to start as further approvals are obtained.

IHL-42X previously received Fast Track designation from the U.S. FDA. An earlier Phase 2 study showed statistically significant reductions in Apnea-Hypopnea Index versus placebo, with reductions of up to 83%, and improvements in patient‑reported outcomes such as fatigue and sleep-related impairment while maintaining a favorable safety profile.

DReAMzz is designed to optimize dosing and further link objective sleep metrics with patient-reported outcomes, generating data intended to support Phase III development and strengthen both the regulatory and commercial positioning of IHL-42X in a condition affecting an estimated one billion people globally.

Incannex Healthcare Inc. reports that the U.S. Patent and Trademark Office has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea” covering its proprietary IHL-42X oral combination therapy and related treatment methods. The patent has a baseline expiry date of 9 July 2040, and the company is exploring the potential for patent term extension following possible U.S. FDA approval. IHL-42X already has FDA Fast Track designation and positive Phase II data, and is advancing toward the DReAMzz Phase 2 dose optimisation study, which is intended to refine dosing and inform a planned Phase III program. Incannex describes obstructive sleep apnoea as a substantially underserved condition affecting an estimated one billion people globally, and views the strengthened U.S. patent position and ongoing clinical progress as enhancing the long-term commercial and strategic value of IHL-42X.

Incannex Healthcare Inc. reported receiving A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program for FY25 and expects a further approximately A$5.1 million in 2026. Combined, management highlights more than A$11.1 million in non-dilutive funding arriving in 2026.

The company notes that this cash is being received without issuing additional shares or taking on debt, supporting its debt-free balance sheet and existing cash position. Management states that the proceeds will help advance key clinical programs, including the DReAMzz study for lead candidate IHL-42X in obstructive sleep apnea, as well as IHL-675A for inflammatory conditions and PSX-001 for generalized anxiety disorder, while also supporting an active share repurchase program.